Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Total thyroidectomy can still remain the method of choice in some Bethesda III cases

J. Lukas, B. Hintnausova, V. Sykorova, M. Syrucek, M. Maly, J. Duskova

. 2023 ; 167 (1) : 61-68. [pub] 20210720

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23002215

BACKGROUND: The latest WHO classification of tumours of endocrine organs defines new units of borderline thyroid tumours (BTT). The aim of our study was to evaluate ultrasonographic and cytological features, mutation profile and surgery treatment in rare thyroid tumours. METHODS: An analysis of 8 BTT out of 487 patients, who underwent thyroid surgery between June 2016 and June 2020. The definitive diagnosis was made postoperatively by extensive histopathological examination. Molecular genetic analysis of genes associated with thyroid oncology (BRAF, HRAS, KRAS, NRAS, TERT, TP53, fused genes) were performed from one FNAB, and 7 formalin-fixed paraffin-embedded (FFPE) samples. RESULTS: BTT were found in a total of 8 patients (1.6%), with a predominance of men with respect to other operated patients. FNAB samples were classified in the Bethesda system as Bethesda I, Bethesda II and Bethesda III in one, four and three cases, respectively. Hemithyroidectomy and total thyroidectomy were performed equally in four patients. The histopathological diagnosis revealed non-invasive encapsulated follicular neoplasm with papillary-like nuclear features (NIFTP) in three patients, follicular tumour of uncertain malignant potential (FT-UMP) in three patients, well differentiated tumour of uncertain malignant potential (WDT-UMP) in one patient, and hyalinizing trabecular tumour (HTT) in one case. In NIFTP cases mutation in HRAS gene in one patient together with probable pathogenic variant in TP53 gene and in NRAS gene in two patients were detected. In HTT patient PAX8/GLIS3 fusion gene was detected. CONCLUSION: The surgical treatment of BTT is necessarily individual influenced by preoperative clinical, ultrasonographic, cytological and molecular genetic findings, and the presence of other comorbidities.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002215
003      
CZ-PrNML
005      
20230517134549.0
007      
ta
008      
230406s2023 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.045 $2 doi
035    __
$a (PubMed)34282807
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lukáš, Jindřich $u Department of Otolaryngology-Head and Neck Surgery, Na Homolce Hospital, Prague, Czech Republic $u Ear, Nose, and Throat Department, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic $7 mzk2005269599
245    10
$a Total thyroidectomy can still remain the method of choice in some Bethesda III cases / $c J. Lukas, B. Hintnausova, V. Sykorova, M. Syrucek, M. Maly, J. Duskova
520    9_
$a BACKGROUND: The latest WHO classification of tumours of endocrine organs defines new units of borderline thyroid tumours (BTT). The aim of our study was to evaluate ultrasonographic and cytological features, mutation profile and surgery treatment in rare thyroid tumours. METHODS: An analysis of 8 BTT out of 487 patients, who underwent thyroid surgery between June 2016 and June 2020. The definitive diagnosis was made postoperatively by extensive histopathological examination. Molecular genetic analysis of genes associated with thyroid oncology (BRAF, HRAS, KRAS, NRAS, TERT, TP53, fused genes) were performed from one FNAB, and 7 formalin-fixed paraffin-embedded (FFPE) samples. RESULTS: BTT were found in a total of 8 patients (1.6%), with a predominance of men with respect to other operated patients. FNAB samples were classified in the Bethesda system as Bethesda I, Bethesda II and Bethesda III in one, four and three cases, respectively. Hemithyroidectomy and total thyroidectomy were performed equally in four patients. The histopathological diagnosis revealed non-invasive encapsulated follicular neoplasm with papillary-like nuclear features (NIFTP) in three patients, follicular tumour of uncertain malignant potential (FT-UMP) in three patients, well differentiated tumour of uncertain malignant potential (WDT-UMP) in one patient, and hyalinizing trabecular tumour (HTT) in one case. In NIFTP cases mutation in HRAS gene in one patient together with probable pathogenic variant in TP53 gene and in NRAS gene in two patients were detected. In HTT patient PAX8/GLIS3 fusion gene was detected. CONCLUSION: The surgical treatment of BTT is necessarily individual influenced by preoperative clinical, ultrasonographic, cytological and molecular genetic findings, and the presence of other comorbidities.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a tyreoidektomie $7 D013965
650    12
$a folikulární adenokarcinom $x patologie $7 D018263
650    12
$a nádory štítné žlázy $x genetika $x chirurgie $x patologie $7 D013964
650    _2
$a uridinmonofosfát $7 D014542
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hintnausová, Barbora $u Department of Endocrinology, Na Homolce Hospital, Prague, Czech Republic $7 xx0230501
700    1_
$a Sýkorová, Vlasta $u Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic $7 xx0118026
700    1_
$a Syrůček, Martin $u Department of Pathology, Na Homolce Hospital, Prague, Czech Republic $7 xx0145890
700    1_
$a Malý, Marek, $u Department of Biostatistics, National Institut of Public Health, Prague, Czech Republic $d 1961- $7 jn20001103265
700    1_
$a Dušková, Jaroslava, $u Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $d 1952- $7 jo2002104714
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 1 (2023), s. 61-68
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34282807 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20230406 $b ABA008
991    __
$a 20230517134544 $b ABA008
999    __
$a ok $b bmc $g 1933543 $s 1188421
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 167 $c 1 $d 61-68 $e 20210720 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK198 $a Pubmed-20230406

Find record

Citation metrics

Archiving options